1-20 of 106
L White
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Asciminib is a novel inhibitor of ABL1 and ABL2 gene fusions in ALL but requires the ABL SH3 domain for efficacy

Laura N. Eadie, Elias Lagonik, Elyse C. Page, Caitlin E. Schutz, Susan L. Heatley, Barbara J. McClure, Michelle O. Forgione, David T. Yeung, Timothy P. Hughes, Deborah L. White
Journal: Blood
Blood (2024) 144 (9): 1022–1026.
https://doi.org/10.1182/blood.2024024776
Published: 2024
Includes: Supplemental data
Journal Articles

Improved MRD Negativity Rates in Adverse Genomic Risk B-ALL Patients with Chemotherapy / Blinatumomab Induction: Experience from the Australasian Leukaemia Lymphoma Group (ALLG) ALL06/09 Studies

Deborah L White, Jacqueline A Rehn, Caitlin E Schutz, Susan L Heatley, Laura N Eadie, Ashlee Thomson, Elyse C Page, Michael Osborn, Shane Gangatharan, Ashley P Ng, Shaun Fleming, Pasquale Fedele, Toby Trahair, John Casey, Sally Mapp, Carol CY Cheung, Tasman Armytage, Michelle Henderson, Rosemary Sutton, Stephen Robert Larsen, Peter Presgrave, John Kwan, Samuel Bennett, Chun Yew Fong, Luciano Dalla-Pozza, David T Yeung, Matthew Greenwood
Journal: Blood
Blood (2023) 142 (Supplement 1): 1609.
https://doi.org/10.1182/blood-2023-178473
Published: 2023
Journal Articles

Synergy of Ruxolitinib and Carfilzomib in Targeting the PAX5::JAK2 fusion I n Vitro : Potential Therapeutic Advantage for a Subset of Ph-like Acute Lymphoblastic Leukemia

Jane Frances Thompson, David T Yeung, Randall Hilton Grose, Deborah L White
Journal: Blood
Blood (2023) 142 (Supplement 1): 5806.
https://doi.org/10.1182/blood-2023-174423
Published: 2023
Journal Articles

Asciminib Is Effective Against ABL1 Gene Fusions in Acute Lymphoblastic Leukemia but Only When the ABL1 SH3 Domain Is Present

Laura N Eadie, Caitlin E Schutz, Elyse C Page, Tace S Conlin, Susan L Heatley, Elias Lagonik, Jacqueline A Rehn, David T Yeung, Timothy P Hughes, Deborah L White
Journal: Blood
Blood (2023) 142 (Supplement 1): 1602.
https://doi.org/10.1182/blood-2023-184647
Published: 2023
Journal Articles

PTPN11 Mutations Drive Tyrosine Kinase Inhibitor As Well As Venetoclax Resistance in Ph+ ALL Cells, but Are Sensitive to the Combination

Govinda Poudel, David T Yeung, Deborah L White, Timothy Hughes, Ilaria S Pagani
Journal: Blood
Blood (2022) 140 (Supplement 1): 3128–3129.
https://doi.org/10.1182/blood-2022-162194
Published: 2022
Journal Articles

Lentiviral Gene Therapy with Low Dose Conditioning for X-Linked SCID Results in Complete Immune Reconstitution and No Evidence of Clonal Expansion

Claire Booth, Donald B. Kohn, Myriam Armant, Susan Prockop, Karen Buckland, Sharat Chandra, Shanmuganathan Chandrakasan, Kritika Chetty, Colleen Dansereau, Satiro de Oliveira, John Everett, Diego León Rico, Wendy B. London, Jin Hua Xu-Bayford, Theodore B. Moore, Nisha Nagarsheth, Suhag Parikh, Dayna Terrazas, Shanna L White, Axel Schambach, Frederic D. Bushman, Adrian J. Thrasher, David A. Williams, Sung-Yun Pai
Journal: Blood
Blood (2022) 140 (Supplement 1): 7770–7771.
https://doi.org/10.1182/blood-2022-159979
Published: 2022
Journal Articles

Induction of Fetal Hemoglobin and Reduction of Clinical Manifestations in Patients with Severe Sickle Cell Disease Treated with Shmir-Based Lentiviral Gene Therapy for Post-Transcriptional Gene Editing of BCL11A: Updated Results from Pilot and Feasibility Trial

Erica B. Esrick, Amy Federico, Daniela Abriss, Myriam Armant, Kari Boardman, Christian Brendel, Marioara-Felicia Ciuculescu, Heather Daley, Colleen Dansereau, Augustine Fernandes, Matthew M. Heeney, David G. Justus, Pei-Chi Kao, Annette S. Kim, Donald B. Kohn, Leslie E. Lehmann, Donghui Liu, Wendy B. London, John P Manis, Theodore B. Moore, Emily Morris, Danilo Pellin, Ellen Proeung, Shanna Richard, Gavin D. Roach, Kit L. Shaw, Dayna Terrazas, Shanna L White, David A. Williams
Journal: Blood
Blood (2022) 140 (Supplement 1): 10665–10667.
https://doi.org/10.1182/blood-2022-169089
Published: 2022
Journal Articles

Enhancer retargeting of CDX2 and UBTF::ATXN7L3 define a subtype of high-risk B-progenitor acute lymphoblastic leukemia

Shunsuke Kimura, Lindsey Montefiori, Ilaria Iacobucci, Yaqi Zhao, Qingsong Gao, Elisabeth M. Paietta, Claudia Haferlach, A. Douglas Laird, Paul E. Mead, Zhaohui Gu, Wendy Stock, Mark Litzow, Jacob M. Rowe, Selina M. Luger, Stephen P. Hunger, Georgina L. Ryland, Breon Schmidt, Paul G. Ekert, Alicia Oshlack, Sean M. Grimmond, Jacqueline Rehn, James Breen, David Yeung, Deborah L. White, Ibrahim Aldoss, Elias J. Jabbour, Ching-Hon Pui, Manja Meggendorfer, Wencke Walter, Wolfgang Kern, Torsten Haferlach, Samuel Brady, Jinghui Zhang, Kathryn G. Roberts, Piers Blombery, Charles G. Mullighan
Journal: Blood
Blood (2022) 139 (24): 3519–3531.
https://doi.org/10.1182/blood.2022015444
Published: 2022
Includes: Supplemental data
Journal Articles

HMGN1 expression Predisposes Down Syndrome Patients to Develop P2RY8-CRLF2 acute Lymphoblastic Leukemia

Elyse C Page, Susan L Heatley, Jacqueline Rehn, David T Yeung, Paul Q Thomas, Deborah L White
Journal: Blood
Blood (2021) 138 (Supplement 1): 4332.
https://doi.org/10.1182/blood-2021-151848
Published: 2021
Journal Articles

Modeling Relapsed, Refractory Acute Lymphoblastic Leukemia from a Child with Neurofibromatosis

Susan L Heatley, Elyse C Page, Laura N Eadie, Barbara J McClure, Jacqueline Rehn, David T Yeung, Michael Philip Osborn, Tamas Revesz, Maria Kirby, Deborah L White
Journal: Blood
Blood (2021) 138 (Supplement 1): 1317.
https://doi.org/10.1182/blood-2021-150086
Published: 2021
Journal Articles

Persistent Activation of JAK/STAT Signaling Plays an Important Role in in Vitro Jaki Resistance in TYK2- rearranged B-Cell Acute Lymphoblastic Leukaemia

Paniz Tavakoli, Laura N Eadie, BSc, PhD, Susan L Heatley, PhD MD, John B Bruning, BSc,PhD, Deborah L White, PhDFFSc(RCPA)
Journal: Blood
Blood (2020) 136 (Supplement 1): 3.
https://doi.org/10.1182/blood-2020-139048
Published: 2020
Journal Articles

Acquired Mutations within the JAK2 Kinase Domain Confer Resistance to JAK Inhibitors in an in Vitro model of a High-Risk Acute Lymphoblastic Leukemia

Charlotte EJ Downes, BS, Barbara J McClure, BSc,PhD, Jacqueline Rehn, MSc(BioTech), James Breen, BSc,PhD, John B Bruning, BSc,PhD, David T Yeung, BSc,PhDFRACP,FRCPA,MBBS, Deborah L White, PhDFFSc(RCPA)
Journal: Blood
Blood (2020) 136 (Supplement 1): 5–6.
https://doi.org/10.1182/blood-2020-133491
Published: 2020
Journal Articles

Next Generation Genomic Analyses in T-ALL Patients Identify Recurrent and Novel Genomic Abnormalities

Laura N Eadie, BSc, PhD, Jacqueline Rehn, MSc(BioTech), Susan L Heatley, PhD MD, Barbara J McClure, BSc,PhD, Caitlin Schutz Schutz, BSc (Hons), James Breen, BSc,PhD, Timothy P. Hughes, MDMBBS,FRACP,FRCPA, David T Yeung, BSc,PhDFRACP,FRCPA,MBBS, Rosemary Sutton, BSc MSc PhD, Deborah L White, PhDFFSc(RCPA)
Journal: Blood
Blood (2020) 136 (Supplement 1): 13–14.
https://doi.org/10.1182/blood-2020-138995
Published: 2020
Journal Articles

Inducible Knockout of HMGN1 in an In Vivo xenograft Model Reduces Down Syndrome Leukemic Burden and Increases Survival Outcomes

Elyse C Page, BSc, Susan L Heatley, PhD MD, Paul Q Thomas, PhD, Deborah L White, PhDFFSc(RCPA)
Journal: Blood
Blood (2020) 136 (Supplement 1): 25.
https://doi.org/10.1182/blood-2020-138620
Published: 2020
Journal Articles

A Novel Role for HMGN1 in Down Syndrome Acute Lymphoblastic Leukemia

Elyse C Page, BSc, Susan L Heatley, PhD MD, David T Yeung, PhDBSc,FRACP,FRCPA,MBBS, Paul Q Thomas, PhD, Deborah L. White, PhD FFSc (RCPA)
Journal: Blood
Blood (2019) 134 (Supplement_1): 1462.
https://doi.org/10.1182/blood-2019-126244
Published: 2019
Journal Articles

Poor Prognosis in Children with ABL -Class Fusion Positive B-Cell Acute Lymphoblastic Leukemia Treated According to AIEOP-BFM Protocols

Gunnar Cario, MD PhD, Veronica Leoni, Valentino Conter, MD, Andishe Attarbaschi, MD, Marketa Zaliova, MD PhD, Lucie Sramkova, Giovanni Cazzaniga, PhD, Grazia Fazio, Rosemary Sutton, BSc MSc PhD, Sarah Elitzur, MD, Shai Izraeli, MD, Melchior Lauten, Franco Locatelli, MD PhD, Giuseppe Basso, MD PhD, Barbara Buldini, MD PhD, Anke K Bergmann, Jana Lentes, Doris Steinemann, Gudrun Gohring, Brigitte Schlegelberger, MD, Oskar A Haas, Denis Martin Schewe, Swantje Buchmann, Anja Moericke, Deborah L. White, PhD FFSc (RCPA), Tamas Revesz, Martin Stanulla, Georg Mann, MD, Nicole Bodmer, Nira Arad-Cohen, Jan Zuna, Maria Grazia Valsecchi, PhD, Martin Zimmermann, PhD, Martin Schrappe, MD PhD, Andrea Biondi, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1351.
https://doi.org/10.1182/blood-2019-126523
Published: 2019
Journal Articles

In Vitro -Selected Nanobody-Based Cellular Therapy Targeting CD72 for Treatment of Refractory B-Cell Malignancies

Matthew Nix, PhD, Yu-Hsiu T. Lin, BA, Huimin Geng, PhD, Makeba Marcoulis, BA, Paul Phojanakong, BA, Donghui Wang, BA, Veronica Steri, PhD, Jeffrey Whitman, MD, Sagar Bapat, MD PhD, Elliot Stieglitz, MD, Anne Deucher, MD PhD, Kristie L White, MD MD, Byron C Hann, MD PhD, Arun P. Wiita, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1337.
https://doi.org/10.1182/blood-2019-130938
Published: 2019
Journal Articles

Pro-Active Dasatinib Dose Reduction Based on Trough Levels May Minimise Toxicity and Preserve Efficacy - Interim Analysis of the ALLG CML 12 Direct Study

David T Yeung, PhDBSc,FRACP,FRCPA,MBBS, Andrew Grigg, Naranie Shanmuganathan, MBBS FRACP FRCPA, Ann Christine Solterbeck, BSc(Hons) MSc PhDAstat, Deborah L. White, PhD FFSc (RCPA), Susan Branford, PhD FFSc (RCPA), Nicholas Viiala, MBBS FRACP FRCPA, Philip Arthur Rowlings, FRACP,FRCPA,MBBS,MS, Anthony K Mills, FRACP, FRCPA, MBBS, Jake Shortt, MBBS FRACP FRCPA PhD, Campbell Tiley, MBBS, FRACP, David M Ross, MD PhD, David Kipp, MBBS,FRCPA,FRACP, Rosemary Anne Harrup, MBBS, FRACP, FRCPA, Ilona Cunningham, MBBS FRACP FRCPA, John Kwan, MBBS,FRACP,FRCPA, Richard Eek, MBChB MMED, FCP, FRACP., Howard Mutsando, MBChB FRACP FRCPA, Ken-Soon Tan, MMed FRACP MRCP(UK) MA MBBChir BA(Hons), Kate Burbury, MBBS, FRACP, FRCPA, DPhil, Matthew P.F. Wright, MBBS, FRCPA, FRACP, Timothy P. Hughes, MDMBBS,FRACP,FRCPA, On Behalf of the ALLG
Journal: Blood
Blood (2019) 134 (Supplement_1): 4150.
https://doi.org/10.1182/blood-2019-127619
Published: 2019
Journal Articles

High Risk Genomic Alterations Identified at the Time of Diagnosis Are Strongly Associated with MRD and Subsequent Poor Outcomes in AYA ALL Patients Treated on a Pediatric Inspired Chemotherapy Regimen

David T Yeung, PhDBSc,FRACP,FRCPA,MBBS, Matthew Greenwood, MBBS, FRACP, FRCPA, Jacqueline Rhen, BSc MSc MD, Susan L Heatley, PhD MD, Barbara McClure, BSc (Hons) PhD, Laura N Eadie, BSc (Hons) PhD, Jimmy Breen, BSc (Hons) PhD, Caitlin Schutz Schutz, BSc (Hons), Toby N Trahair, MBBS FRACP PhD, Andrew H. Wei, PhD FRACP, FRCPA, MBBS, Luciano Dalla-Pozza, MBBS FRACP, Rosemary Sutton, BSc MSc PhD, Kenneth F Bradstock, BSc(MD, MBBS, PhD FRACP, FRCPA, Michael Philip Osborn, MB, BS, Deborah L. White, PhD FFSc (RCPA)
Journal: Blood
Blood (2019) 134 (Supplement_1): 3949.
https://doi.org/10.1182/blood-2019-127788
Published: 2019
Journal Articles

Azacytidine Sensitizes AML Cells for Effective Elimination By CD123 CAR T-Cells

Nadia El Khawanky, Bsc(Biomed), BHlthSc(Hons), Amy Hughes, PhD, Wenbo Yu, PhD, Sanaz Taromi, PhD, Jade Clarson, BSc, Angel F. Lopez, MD PhD, Michael P. Brown, MD PhD, Justus Duyster, MD, Timothy P. Hughes, MDMBBS,FRACP,FRCPA, Deborah L. White, PhD FFSc (RCPA), Agnes S. M. Yong, MD PhD, Robert Zeiser, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3904.
https://doi.org/10.1182/blood-2019-124684
Published: 2019